A recent study reveals that people who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end conventional lifestyle programs.
Findings released in a leading health publication points out that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing such treatments should be aware of the risk of quick rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment mass within about one and a half years.
Weighing Treatments
The study, which reviewed 37 of studies involving thousands of patients, contrasted the results of these new drugs with other pills.
Scientists emphasize that individuals who lose weight through lifestyle changes alone usually experience a more gradual creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Doctors suggest the mechanism of the drugs is key to understanding the heightened rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication leads to appetite is no longer kept in check, making overeating a significant risk."
A Chronic Condition?
Medical guidelines recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals say that, due to the high risk of relapse, the treatment might need to be ongoing.
This perspective is supported by pharmaceutical companies, who note that the findings "emphasize the long-term nature of excess weight," similar to managing diseases like diabetes.
User Experiences
Users who have discontinued the jabs describe a sudden return of appetite.
"It felt as if a switch that goes on and you're instantly ravenous," described one woman.
The struggle is exacerbated if users have not established sustainable lifestyle or habit changes during treatment.
Significant Use
Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is higher among females than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians stress that while the jabs are potent tools for weight loss, they are not a standalone solution and lasting health benefits hinges on combined behavioural management.
